Sensus Healthcare (NasdaqCM:SRTS) - Share price, News & Analysis

SRTS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

SRTS Stock Overview

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

Rewards

Price-To-Earnings ratio (6.3x) is below the US market (14.7x)

Revenue is forecast to grow 9.1% per year

Became profitable this year

Risk Analysis

Earnings are forecast to decline by an average of 45.6% per year for the next 3 years

High level of non-cash earnings

Significant insider selling over the past 3 months

Sensus Healthcare Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sensus Healthcare
Historical stock prices
Current Share Price	US$8.02
52 Week High	US$11.96
52 Week Low	US$3.21
Beta	0.50
1 Month Change	-10.29%
3 Month Change	-29.96%
1 Year Change	82.27%
3 Year Change	44.77%
5 Year Change	99.50%
Change since IPO	37.09%

Recent News & Updates

May 21

Sensus Healthcare: A Buy In Honor Of Skin Cancer Awareness Month

Sensus has developed an FDA-cleared laser device that targets non-melanoma skin cancers and keloids. While 2021 was a tough time for the company as elective procedures non-existent during the pandemic. However, a swift rebound occurred of late that has driven revenues and earnings to all-time highs. I believe this trend will continue thanks to advantageous tech platform, TAM, and operational excellence.

May 11

Analysts Just Made A Captivating Upgrade To Their Sensus Healthcare, Inc. (NASDAQ:SRTS) Forecasts

Sensus Healthcare, Inc. ( NASDAQ:SRTS ) shareholders will have a reason to smile today, with the analysts making...

Apr 29

Investors Will Want Sensus Healthcare's (NASDAQ:SRTS) Growth In ROCE To Persist

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...

Shareholder Returns

	SRTS	US Medical Equipment	US Market
7D	5.2%	7.0%	6.6%
1Y	82.3%	-23.6%	-18.4%

Return vs Industry: SRTS exceeded the US Medical Equipment industry which returned -23.7% over the past year.

Return vs Market: SRTS exceeded the US Market which returned -18.5% over the past year.

Price Volatility

Is SRTS's price volatile compared to industry and market?
SRTS volatility
SRTS Average Weekly Movement	11.1%
Medical Equipment Industry Average Movement	10.4%
Market Average Movement	8.1%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.2%

Stable Share Price: SRTS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: SRTS's weekly volatility (11%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2010	37	Joe Sardano	https://www.sensushealthcare.com

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Sensus Healthcare Fundamentals Summary

How do Sensus Healthcare's earnings and revenue compare to its market cap?
SRTS fundamental statistics
Market Cap	US$133.75m
Earnings (TTM)	US$21.30m
Revenue (TTM)	US$34.31m

6.3x

P/E Ratio

3.9x

P/S Ratio

Is SRTS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
SRTS income statement (TTM)
Revenue	US$34.31m
Cost of Revenue	US$11.76m
Gross Profit	US$22.55m
Other Expenses	US$1.26m
Earnings	US$21.30m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	1.28
Gross Margin	65.73%
Net Profit Margin	62.07%
Debt/Equity Ratio	0%

How did SRTS perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is SRTS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SRTS?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for SRTS. This is calculated by dividing SRTS's market cap by their current preferred multiple.
What is SRTS's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	US$133.75m

SRTS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3x
Enterprise Value/EBITDA	10.5x
PEG Ratio	-0.1x

Price to Earnings Ratio vs Peers

How does SRTS's PE Ratio compare to its peers?

SRTS PE Ratio vs Peers

The above table shows the PE ratio for SRTS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PE	Estimated Growth	Market Cap
Peer Average	251x

Forward PE

Price-To-Earnings vs Peers: SRTS is good value based on its Price-To-Earnings Ratio (6.3x) compared to the peer average (251x).

Price to Earnings Ratio vs Industry

How does SRTS's PE Ratio compare vs other companies in the U.S. Medical Equipment Industry?

Price-To-Earnings vs Industry: SRTS is good value based on its Price-To-Earnings Ratio (6.3x) compared to the US Medical Equipment industry average (34.8x)

Price to Earnings Ratio vs Fair Ratio

What is SRTS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SRTS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	6.3x
Fair PE Ratio	6.2x

Price-To-Earnings vs Fair Ratio: SRTS is expensive based on its Price-To-Earnings Ratio (6.3x) compared to the estimated Fair Price-To-Earnings Ratio (6.2x).

Share Price vs Fair Value

What is the Fair Price of SRTS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SRTS ($8.02) is trading above our estimate of fair value ($3.13)

Significantly Below Fair Value: SRTS is trading above our estimate of fair value.

Price to Earnings Growth Ratio

PEG Ratio: SRTS's earnings are forecast to decline next year, so we can't calculate its PEG ratio.

Discover undervalued companies

Future Growth

How is Sensus Healthcare forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-45.6%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SRTS's earnings are forecast to decline over the next 3 years (-45.6% per year).

Earnings vs Market: SRTS's earnings are forecast to decline over the next 3 years (-45.6% per year).

High Growth Earnings: SRTS's earnings are forecast to decline over the next 3 years.

Revenue vs Market: SRTS's revenue (9.1% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: SRTS's revenue (9.1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SRTS's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Past Performance

How has Sensus Healthcare performed over the past 5 years?

Past Performance Score

3/6

Past Performance Score 3/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

34.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: SRTS has a high level of non-cash earnings.

Growing Profit Margin: SRTS became profitable in the past.

Past Earnings Growth Analysis

Earnings Trend: SRTS has become profitable over the past 5 years, growing earnings by 34.4% per year.

Accelerating Growth: SRTS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: SRTS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).

Return on Equity

High ROE: SRTS's Return on Equity (50.2%) is considered outstanding.

Discover strong past performing companies

Financial Health

How is Sensus Healthcare's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: SRTS's short term assets ($48.5M) exceed its short term liabilities ($10.3M).

Long Term Liabilities: SRTS's short term assets ($48.5M) exceed its long term liabilities ($1.2M).

Debt to Equity History and Analysis

Debt Level: SRTS is debt free.

Reducing Debt: SRTS has no debt compared to 5 years ago when its debt to equity ratio was 11%.

Debt Coverage: SRTS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: SRTS has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

Dividend

What is Sensus Healthcare current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate SRTS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SRTS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SRTS's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SRTS's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SRTS has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure

CEO

Joe Sardano (68 yo)

12yrs

Tenure

US$630,451

Compensation

Mr. Joseph C. Sardano, also known as Joe, serves as Director at BioFlorida Inc since August 2021. He Co-Founded Sensus Healthcare, Inc. in 2010 and has been its Chairman of the Board, Chief Executive Offic...

CEO Compensation Analysis

Compensation vs Market: Joe's total compensation ($USD630.45K) is about average for companies of similar size in the US market ($USD752.25K).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: SRTS's management team is considered experienced (2.4 years average tenure).

Board Members

Experienced Board: SRTS's board of directors are considered experienced (9.6 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: SRTS insiders have only sold shares in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/06/26 00:00
End of Day Share Price	2022/06/24 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31